Novo Nordisk A/S Common Stock (NVO)

The healthcare sector has entered a period of sharp divergence in early 2026, creating a "bifurcated market" where clinical innovation is rewarding a select few while punishing former industry darlings. As of March 10, 2026, the industry is processing a tale of two trajectories: Vertex Pharmaceuticals (NASDAQ: VRTX) has cemented

The long-held dominance of Novo Nordisk (NYSE: NVO) in the global obesity market has been dealt a staggering blow following the release of the "worst-case scenario" results from the REDEFINE 4 Phase 3 trial. For years, the Danish pharmaceutical giant was the undisputed leader of the GLP-1 revolution, but the

As per the CEO, the company will have four late-stage trials by the end of 2026.

These companies' shares have fallen too far, offering investors an attractive opportunity.

As of today, March 10, 2026, Pfizer Inc. (NYSE: PFE) stands at a pivotal crossroads in its 177-year history. After experiencing a meteoric rise during the COVID-19 pandemic followed by a sobering "hangover" period in 2023 and 2024, the pharmaceutical giant is currently in the middle of a high-stakes transformation. The company is attempting to [...]

As of March 10, 2026, the telehealth landscape has undergone a radical transformation, and few companies embody this shift more than Hims & Hers Health, Inc. (NYSE: HIMS). Once dismissed as a "wellness-lite" platform for hair loss and erectile dysfunction, Hims & Hers has evolved into a diversified healthcare titan. Today, the company finds itself [...]

BMO Capital maintained its ‘Market Perform’ rating for Novo Nordisk, with a price target of $45, implying an upside of more than 13% from NVO stock’s closing price on Monday.

Short interest totalled about $1.39 billion, or roughly 42.83% of the float, according to S3 Partners.

Hims & Hers stock traded more than 40% higher after the deal was announced.

The price of the company's popular GLP-1 drugs could come down by as much as 50% next year.

Hims & Hers shares are up over 40% on Monday after announcing a deal with Novo Nordisk.

Hims & Hers also stated that it will no longer advertise compounded GLP-1 offerings on its platform or in its marketing.

Lupton Capital CEO Jonah Lupton said the potential agreement could include both injectable and oral GLP-1 drugs.

They may appeal to different kinds of investors.

These companies have a lot more to offer than their prospects in the weight loss market.

Things can't get that much worse for the drugmaker.

According to J.P. Morgan, the market for weight-loss drugs will become one of the biggest and fastest-growing in healthcare.

Novo Nordisk looks cheap, but a rebound hinges on fixing execution and management credibility.

Novo Nordisk's Kagrama stumbles versus Zepbound, forcing investors to reassess obesity‑drug expectations.

NEW YORK — The era of easy access to compounded weight-loss "knockoffs" is rapidly drawing to a close, leaving the telehealth industry’s once-shining star, Hims & Hers Health, Inc. (NYSE: HIMS), in a precarious regulatory and legal bind. As of March 4, 2026, the company finds itself at a crossroads, battling

The notice comes weeks after a similar warning over Wegovy advertising, as the FDA ramps up scrutiny of marketing tied to GLP-1 drugs.

Lilly is leading the pack in the GLP-1 race, but this isn't a sprint, and you should consider more than just weight loss drugs.

Why does the shortest month of the year sometimes feel like the longest?

The stock is down big of late, but the business is by no means doomed.